Works matching AU Nakamura, Yoichi


Results: 140
    1
    2
    3
    4
    5
    6
    7
    8

    Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.

    Published in:
    Oncologist, 2022, v. 27, n. 11, p. 903, doi. 10.1093/oncolo/oyac193
    By:
    • Chihara, Yusuke;
    • Takeda, Takayuki;
    • Goto, Yasuhiro;
    • Nakamura, Yoichi;
    • Tsuchiya-Kawano, Yuko;
    • Nakao, Akira;
    • Onoi, Keisuke;
    • Hibino, Makoto;
    • Fukuda, Minoru;
    • Honda, Ryoichi;
    • Yamada, Takahiro;
    • Taniguchi, Ryusuke;
    • Sakamoto, Sinjiro;
    • Date, Koji;
    • Nagashima, Seiji;
    • Tanzawa, Shigeru;
    • Minato, Koichi;
    • Nakatani, Koichi;
    • Izumi, Miiru;
    • Shimose, Takayuki
    Publication type:
    Article
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19

    Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer.

    Published in:
    Cancer Medicine, 2021, v. 10, n. 2, p. 626, doi. 10.1002/cam4.3641
    By:
    • Shimokawa, Tsuneo;
    • Yamada, Kazuhiko;
    • Tanaka, Hiroshi;
    • Kubota, Kaoru;
    • Takiguchi, Yuichi;
    • Kishi, Kazuma;
    • Saito, Haruhiro;
    • Hosomi, Yukio;
    • Kato, Terufumi;
    • Harada, Daijiro;
    • Otani, Sakiko;
    • Kasai, Takashi;
    • Nakamura, Yoichi;
    • Misumi, Toshihiro;
    • Yamanaka, Takeharu;
    • Okamoto, Hiroaki
    Publication type:
    Article
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30

    A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2014, v. 74, n. 3, p. 497, doi. 10.1007/s00280-014-2527-4
    By:
    • Ikeda, Takaya;
    • Fukuda, Minoru;
    • Nakamura, Yoichi;
    • Kinoshita, Akitoshi;
    • Senju, Hiroaki;
    • Nakano, Hirofumi;
    • Kitazaki, Takeshi;
    • Ogawara, Daiki;
    • Taniguchi, Hirokazu;
    • Motoshima, Kohei;
    • Yamaguchi, Hiroyuki;
    • Nakatomi, Katsumi;
    • Shimada, Midori;
    • Nagashima, Seiji;
    • Tsukamoto, Kazuhiro;
    • Kohno, Shigeru
    Publication type:
    Article
    31
    32

    Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2013, v. 72, n. 6, p. 1299, doi. 10.1007/s00280-013-2307-6
    By:
    • Motoshima, Kohei;
    • Nakamura, Yoichi;
    • Sano, Kazumi;
    • Ikegami, Yoji;
    • Ikeda, Takaya;
    • Mizoguchi, Kosuke;
    • Takemoto, Shinnosuke;
    • Fukuda, Minoru;
    • Nagashima, Seiji;
    • Iida, Tetsuya;
    • Tsukamoto, Kazuhiro;
    • Kohno, Shigeru
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39
    40
    41

    Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure.

    Published in:
    Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-19371-6
    By:
    • Ejiri, Kentaro;
    • Miyoshi, Toru;
    • Kihara, Hajime;
    • Hata, Yoshiki;
    • Nagano, Toshihiko;
    • Takaishi, Atsushi;
    • Toda, Hironobu;
    • Namba, Seiji;
    • Nakamura, Yoichi;
    • Akagi, Satoshi;
    • Sakuragi, Satoru;
    • Minagawa, Taro;
    • Kawai, Yusuke;
    • Nishii, Nobuhiro;
    • Fuke, Soichiro;
    • Yoshikawa, Masaki;
    • Nakamura, Kazufumi;
    • Ito, Hiroshi;
    • Sato, Tetsuya;
    • Sugiyama, Hiroyasu
    Publication type:
    Article
    42
    43
    44
    45
    46
    47
    48
    49
    50